Designing Phase 1 Studies When the Site Is Digital

Phase 1 trials are where risk lives. Not because things are reckless, but because these are first-in-human studies. Doses are low, but uncertainty is high. Which makes it even more important to get monitoring, communication and compliance right. Traditionally, these trials have been run in tightly controlled environments. But what happens when the site goes digital?

‍

You can’t just lift a Phase 1 protocol and move it into the cloud. The same tools, even the same logic, don’t always apply. Remote execution needs different foundations. And even when a trial stays hybrid - with some site visits and some remote elements - designing for safety becomes a different kind of exercise.

‍

Oversight and early signal detection

In early-phase studies, time is everything. Investigators and sponsors need fast access to safety data. Not just summaries, but the actual entries. Digital tools need to:

• Show individual participant data in near real time
• Flag trends like elevated vitals, symptom clusters or missed tasks
• Enable central staff to reach out immediately if something looks wrong

Static dashboards aren’t enough. These studies require watchfulness. Not just analysis.

‍

Participant communication that moves fast

Someone misses a dose. Someone skips a check-in. Someone logs a side effect at 10:47pm. Who sees it? What happens next?

In traditional studies, the site nurse hears about it the next morning. In a digital study, the response needs to be faster and more structured. That might mean:

• A direct messaging channel between participant and study team
• Tiered alerts for different types of symptoms
• Pre-written escalation plans built into the system

‍

Dose escalation logic that’s visible

Phase 1 often means small cohorts, staggered starts and dose escalation. These transitions are hard enough in person. Digitally, they demand careful orchestration. Systems should:

• Track cohort progress against protocol thresholds
• Lock or unlock new tasks based on predefined criteria
• Document investigator sign-off before escalation proceeds

‍

Consent and re-consent without confusion

Early-phase trials often evolve quickly. Dosing updates. Safety language changes. Participants need to be re-consented more than once.

That requires:

• Consent materials that can be versioned and redistributed quickly
• Timestamped confirmations of review and acceptance
• Interfaces that make it clear which version a participant saw

‍

Hybrid doesn't mean halfway

Some Phase 1 trials still require on-site dosing or bloodwork. That’s fine. Digital tools can still support these visits without replacing them. For example:

• Site staff enter dosing data directly into an eCRF
• Participants complete follow-up symptom tracking remotely
• Video calls replace phone check-ins to assess wellbeing

The key is not to digitise everything. It’s to digitise the right things. The ones that give investigators visibility and participants support.

‍

Protocol design and platform capability must match

A common failure point is when the protocol assumes everything is centralised, but the tools don’t allow it. Or the reverse - when the platform allows for remote monitoring, but the protocol demands in-person review.

Digital Phase 1 trials work when both layers align. When you can say with confidence:

• We know who is watching the data
• We know how to respond to risk
• We’ve built the system around the need for speed, clarity and certainty

‍

Not every Phase 1 study can or should be decentralised. But when the site goes digital, the design must shift with it. Because safety is not a feature. It’s the foundation.

‍